MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 146 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.91 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $11,622,217 | +64.2% | 50,230 | +3.6% | 1.09% | +80.9% |
| Q3 2023 | $7,078,413 | -33.0% | 48,469 | +6.0% | 0.60% | -52.6% |
| Q2 2023 | $10,565,709 | -72.7% | 45,739 | -65.7% | 1.27% | -78.7% |
| Q4 2022 | $38,693,808 | +269.4% | 133,312 | -17.3% | 5.97% | +191.5% |
| Q3 2022 | $10,474,000 | -0.8% | 161,163 | -4.1% | 2.05% | -0.5% |
| Q2 2022 | $10,554,000 | -30.0% | 168,003 | -22.0% | 2.06% | +12.8% |
| Q1 2022 | $15,072,000 | +6.1% | 215,316 | +28.4% | 1.82% | +11.2% |
| Q4 2021 | $14,208,000 | +8.0% | 167,661 | +1.7% | 1.64% | +0.3% |
| Q3 2021 | $13,154,000 | -18.1% | 164,860 | 0.0% | 1.64% | -50.7% |
| Q2 2021 | $16,059,000 | +21.9% | 164,860 | +46.4% | 3.32% | +0.2% |
| Q1 2021 | $13,171,000 | +4.5% | 112,604 | -0.8% | 3.31% | +40.6% |
| Q4 2020 | $12,608,000 | -7.4% | 113,464 | -1.0% | 2.35% | -46.1% |
| Q3 2020 | $13,614,000 | +2.5% | 114,661 | -2.3% | 4.37% | -3.9% |
| Q2 2020 | $13,288,000 | – | 117,331 | – | 4.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 73,487 | $17,003,422 | 28.29% |
| Tao Capital Management LP | 130,529 | $30,202 | 27.63% |
| Paulson & Co. | 1,105,741 | $255,846,353 | 23.09% |
| AlpInvest Partners B.V. | 211,488 | $48,934,093 | 11.18% |
| Bain Capital Life Sciences Investors, LLC | 324,619 | $75,110,344 | 7.20% |
| Avoro Capital Advisors LLC | 1,888,888 | $437,050,905 | 6.04% |
| Propel Bio Management, LLC | 30,032 | $6,948,804 | 5.76% |
| Baker Brothers Advisors | 1,969,798 | $455,771,861 | 5.19% |
| Rosalind Advisors, Inc. | 25,000 | $5,784,500 | 4.76% |
| TCG Crossover Management, LLC | 179,917 | $41,629,195 | 4.62% |